The 8 analysts offering 12-month price forecasts for Editas Medicine Inc have a median target of 42.50, with a high estimate of 81.00 and a low estimate of 14.00. The median estimate represents a +2.41% increase from the last price of 41.50.
The current consensus among 11 polled investment analysts is to Buy stock in Editas Medicine Inc. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.76
Reporting Date May 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.